Merck (NYSE:MRK) reported new Phase 3 data for belzutifan based WELIREG regimens in renal cell carcinoma, showing meaningful ...
Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer.
Diabetes mellitus is associated with worse RCC outcomes across all outcomes. Metformin use was associated with improved outcomes, but this association is likely substantially affected by time-related ...
We are continuing to see an increase in the incidence of kidney cancer in younger patients over time. Maintaining kidney health involves basic lifestyle choices: avoiding obesity, not smoking, and ...
There are multiple potential applications for circulating tumor (ct)DNA in kidney cancer. The post-nephrectomy remission, adjuvant therapy decision, and monitoring for response or progression on ...
Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancements in diagnosis and prognosis, and personalized treatment for renal cell carcinoma (RCC) session and a presentation ...
Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
Prospective evidence supports SABR as a valid option for localized RCC and suggests SABR with or without immunotherapy has promise in the metastatic setting. Challenging notions of renal cell ...
Using the best medication available in the frontline setting of RCC leads to optimal results. David Braun, MD, of the Yale School of Medicine explores the strategic tension between immediate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results